Pfizer announces that its vaccine candidate is 90% "effective"

Illustration of a coronavirus vaccine.

-

A vaccine developed by Pfizer (United States) and BioNTech (Germany) is 90% “effective” in preventing coronavirus infections according to the large-scale phase 3 trial underway, the last step before an application for approval, jointly announced these companies.

Patient protection was achieved seven days after the second of the two doses and 28 days after the first, according to preliminary results.

“More than eight months after the start of the worst pandemic in more than a century, we believe this step represents a significant step forward for the world in our battle against Covid-19,” said the President and CEO of Pfizer, Albert Bourla, in a statement.

Up to 50 million doses of vaccines worldwide in 2020

“The first set of results from our Phase 3 Covid-19 vaccine trial provide initial evidence of our vaccine's ability to prevent Covid-19,” he adds.

Based on projections, the companies said they plan to deliver up to 50 million doses of the vaccine globally in 2020 and up to 1.3 billion doses in 2021.

In much of the world, rates of Covid-19 infections are reaching record levels, hospital intensive care units are filling up and the death toll continues to rise.

• Vaccine

• Coronavirus

• epidemic

• Covid 19

• Health